Mood Disorders

Navacaprant—a novel, oral, once-daily, highly selective kappa opioid receptor antagonist that is currently in phase 3 development as a monotherapy for major depressive disorder.

What are some key considerations in diagnosing bipolar disorder? Joseph F. Goldberg, MD, shares insights at the recent 2023 Annual Psychiatric Times World CME Conference.

What is new in research on sleep?

How does a patient process their illness and move their way to healing and even creativity?

Black mothers in the US experience far worse outcomes. Here’s what clinicians need to know.

What is the association between the gut microbiome and response to SSRIs in patients with depression?

1 in 5 respondents reported using psychedelic drugs for the purpose of self-treating anxiety, depression, or other mental illnesses.

Check out the evidence for a modest effect over 1 year of clozapine dose on weight.

PME affects many women, yet it remains under-recognized in clinical practice and in research.

In Part III of this series, an expert discusses the key differences between cyclothymia and borderline personality disorder, along with treatment considerations for cyclothymia.

In Part II of this series, an expert discusses cyclothymia and mood temperament in children and adolescents.

In Part I of this new series, an expert provides an overview of cyclothymia and mood temperaments.

What is the current role of lithium?

Catatonia is thought to be significantly underrecognized, and it is important to routinely screen for it among hospitalized patients. Here's how to recognize and treat.

What is the best evidence-based medication treatment for acute bipolar II depression?

Lithium: what’s its history and where do we still need more information?

Catatonia: learn more about how to best diagnose early.

Data on the effects of discontinuing lithium on renal function are scarce and conflicting. A new study exploring these effects may aid in the clinical decision-making process.

From the effects of caffeine on smokers with schizophrenia and bipolar disorder to the initiation of a trial for a new ADHD medication, here are highlights from the week in Psychiatric Times.

Smoking and drinking (caffeine): Researchers analyzed caffeine intake and levels in smokers with schizophrenia and bipolar disorder.

"This study served as a sobering reminder of the significant frequency of this disfiguring and sometimes disabling adverse effect, which can be irreversible."

In the case of antidepressants, a few recent articles may make it tempting to throw the baby out with the bathwater. But on close examination, that would be a mistake on many levels...

"Despite this new study and the need for further research, the best recommendation at this time regarding lithium in patients with bipolar disorder who are suicidal would be to consider it a worthwhile option."

Classic psychedelic research is rapidly expanding...